These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 23782055)

  • 1. Role of ELA region in auto-activation of mutant KIT receptor: a molecular dynamics simulation insight.
    Purohit R
    J Biomol Struct Dyn; 2014; 32(7):1033-46. PubMed ID: 23782055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Function of activation loop tyrosine phosphorylation in the mechanism of c-Kit auto-activation and its implication in sunitinib resistance.
    DiNitto JP; Deshmukh GD; Zhang Y; Jacques SL; Coli R; Worrall JW; Diehl W; English JM; Wu JC
    J Biochem; 2010 Apr; 147(4):601-9. PubMed ID: 20147452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug binding and resistance mechanism of KIT tyrosine kinase revealed by hydrogen/deuterium exchange FTICR mass spectrometry.
    Zhang HM; Yu X; Greig MJ; Gajiwala KS; Wu JC; Diehl W; Lunney EA; Emmett MR; Marshall AG
    Protein Sci; 2010 Apr; 19(4):703-15. PubMed ID: 20095048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A shift of dynamic equilibrium between the KIT active and inactive states causes drug resistance.
    Srikakulam SK; Bastys T; Kalinina OV
    Proteins; 2020 Nov; 88(11):1434-1446. PubMed ID: 32530065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanism of D816X mutation-induced c-Kit activation and -mediated inhibitor resistance in gastrointestinal stromal tumor.
    Jiang H; Shao W; Wang Y; Xu R; Zhou L; Mu X
    J Mol Graph Model; 2018 Sep; 84():189-196. PubMed ID: 30015051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation D816V alters the internal structure and dynamics of c-KIT receptor cytoplasmic region: implications for dimerization and activation mechanisms.
    Laine E; Chauvot de Beauchêne I; Perahia D; Auclair C; Tchertanov L
    PLoS Comput Biol; 2011 Jun; 7(6):e1002068. PubMed ID: 21698178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hotspot mutations in KIT receptor differentially modulate its allosterically coupled conformational dynamics: impact on activation and drug sensitivity.
    Chauvot de Beauchêne I; Allain A; Panel N; Laine E; Trouvé A; Dubreuil P; Tchertanov L
    PLoS Comput Biol; 2014 Jul; 10(7):e1003749. PubMed ID: 25079768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detailed conformational dynamics of juxtamembrane region and activation loop in c-Kit kinase activation process.
    Zou J; Wang YD; Ma FX; Xiang ML; Shi B; Wei YQ; Yang SY
    Proteins; 2008 Jul; 72(1):323-32. PubMed ID: 18214972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT.
    Apsel Winger B; Cortopassi WA; Garrido Ruiz D; Ding L; Jang K; Leyte-Vidal A; Zhang N; Esteve-Puig R; Jacobson MP; Shah NP
    Cancer Res; 2019 Aug; 79(16):4283-4292. PubMed ID: 31270078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of KIT in the management of patients with gastrointestinal stromal tumors.
    Hornick JL; Fletcher CD
    Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor.
    Wang WL; Conley A; Reynoso D; Nolden L; Lazar AJ; George S; Trent JC
    Cancer Chemother Pharmacol; 2011 Jan; 67 Suppl 1():S15-24. PubMed ID: 21181476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of gastrointestinal stromal tumor after imatinib and sunitinib.
    Montemurro M; Bauer S
    Curr Opin Oncol; 2011 Jul; 23(4):367-72. PubMed ID: 21519258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase.
    Foster R; Griffith R; Ferrao P; Ashman L
    J Mol Graph Model; 2004 Oct; 23(2):139-52. PubMed ID: 15363456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib].
    Hong JL; Li J; Li J; Shen L
    Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):386-90. PubMed ID: 22932406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.
    Lee JH; Kim Y; Choi JW; Kim YS
    J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors.
    Janeway KA; Liegl B; Harlow A; Le C; Perez-Atayde A; Kozakewich H; Corless CL; Heinrich MC; Fletcher JA
    Cancer Res; 2007 Oct; 67(19):9084-8. PubMed ID: 17909012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine kinase inhibition: Ligand binding and conformational change in c-Kit and c-Abl.
    Healy EF; Johnson S; Hauser CR; King PJ
    FEBS Lett; 2009 Sep; 583(17):2899-906. PubMed ID: 19660459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular dynamics and molecular docking studies on E166A point mutant, R274N/R276N double mutant, and E166A/R274N/R276N triple mutant forms of class A β-lactamases.
    Kumar KM; Lavanya P; Anbarasu A; Ramaiah S
    J Biomol Struct Dyn; 2014 Dec; 32(12):1953-68. PubMed ID: 24261683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural and functional analysis of KIT gene encoding receptor tyrosine kinase and its interaction with sunitinib and HDAC inhibitors: an in silico approach.
    Vanajothi R; Rajamanikandan S; Sudha A; Srinivasan P
    Pak J Biol Sci; 2012 Feb; 15(3):121-31. PubMed ID: 22866542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.